What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study

Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study                       Paris, 6 July 2020 – 7.00 a.m. CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX) (“Pixium Vision” or the “Company”), a company that dev...

Sensorion appoints Dr Edwin Moses, former Ablynx CEO, as Chairman of the Board

- Dr Moses is internationally recognized as a leading CEO and Chairman of life science companies - Dr Moses led the rapid growth of Ablynx from a platform technology to a fully integrated biopharmaceutical company prior its acquisition by Sanofi - Appointment adds momentum and validation to Sensorion assets and str...

MastOR secures seed funding from Sofinnova Partners to develop its laparoscopy assistance platform

PARIS, FRANCE / ACCESSWIRE / July 2, 2020 -- MastOR, a medical device company developing a surgical robot for laparoscopy assistance, announced today a €3M equity round through a seed investment from the Sofinnova Partners MD Start III Fund, as well as an additional €1.9M in non-dilutive funding through the i-Nov I...

Sofinnova Partners Announces Two First Investments from its MD Start III Medtech Acceleration Fund

Investments in innovative medical devices follow the fund’s initial closing in May 2019   PARIS, France – July 2, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the second investment from its MD Start III Fund, a medtech accelerator...

Redx Pharma: Proposed financing of $30 million via issue of convertible loan notes and share subscription and notice of General Meeting

DJ Redx Pharma plc Proposed financing of $30m and notice of GM   TIDMREDX RNS Number : 4498R Redx Pharma plc 30 June 2020 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULA TION (596/2014). UPON THE PUBLICATION ...

ELSAN partners with Sofinnova MD Start III, an acceleration fund dedicated to healthcare innovation and medical devices

This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects. June 25, 2020 - PARIS, France - ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinno...

Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain

• U.S. commercialization expected to begin in the first half of 2021   • Continues positive momentum for Mainstay, with increasing commercial footprint in Europe and expected launch in Australia in early 2021   June 22, 2020 02:00 AM Eastern Daylight Time DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mai...

Shockwave Announces Pricing of Public Offering of Common Stock

June 16, 2020 at 8:20 PM EDT   SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its common stock at a price to the public of $45.75 per share.

Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)

Daix (France), June 15, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced positive toplin...

Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board

Company announces strategic collaboration with SR-Tiget   MILAN, Italy – June 15, 2020 -- Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced today ...

1 2 3 ... 178